Long-term results and prognostic analysis in advanced and recurrent/refractory epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin with autologous bone marrow transplantation

International Journal of Clinical Oncology

Volumn 4, Issue 5, 1999, Pages 273-279

  Shinozuka, Takao ^a   Muramatsu, Toshinari ^a   Miyamoto, Tsuyoshi ^a   Hirasawa, Takeshi ^a   Murakami, Masaru ^a   Makino, Tsunehisa ^a   Sadahiro, Shotaro ^a   Tanaka, Yutaka ^a   Yasuda, Masanori ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

Autologous bone marrow transplantation; High dose chemotherapy; Long term follow up; Ovarian cancer; Prognostic factor

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032754003     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470050067     Document Type: Article

References (31)

1. Tobias JS, Weiner RS, Griffiths CT, et al. (1977) Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. Eur J Cancer 13:269-277
2. Vriesendorp R, Aalders JG, Sleijfer DT, et al. (1984) Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. Gynecol Oncol 17:271-276
3. Wiltshaw E, Kroner T (1976) Phase II study of cis-dichlorodiammineplatinum (II) (NSC 119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:55-60
4. Bruckner HW, Ratner LH, Cohen CJ, et al. (1978) Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) after failure of initial chemotherapy. Cancer Treat Rep 62:1021-1023
5. Ehrlich CE, Einhorn L, Williams SD, et al. (1979) Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum (II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treat Rep 63:281-288
6. Williams CJ, Stevensen KE, Buchanan RB, et al. (1979) Advanced ovarian carcinoma: a pilot study of cis-dichlorodiammineplatinum (II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as a single agent in previously treated patients. Cancer Treat Rep 63:1745-1753
7. Bruckner HW, Wallach R, Cohen CJ, et al. (1981) High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 12:64-67
8. Ozols RF, Ostchega Y, Myers CE, et al. (1985) High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 3:1246-1250
9. Hacker NF, Berek JS, Lagasse LD, et al. (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61:413-420
10. Delgado G, Oram DH, Petrilli ES (1984) Stage III ovarian cancer: the role of maximal surgical cytoreduction. Gynecol Oncol 18:293-298
11. Murakami M, Shinozuka T, Kuroshima Y, et al. (1994) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumors. Semin Oncol 21 (Suppl 1):s1-29-32
12. Shinozuka T, Miyamoto T, Muramatsu T, et al. (1997) Long-term follow-up and prognostic analysis in epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin and cisplatin (CAP) with autologous bone marrow transplantation (ABMT) (abstract). Proc Am Soc Clin Oncol 16:378
13. Gilmore MJML, Prentice HG, Blacklock HA, et al. (1982) A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizonate and the IBM 2991 blood cell processor. Br J Haematol 50:619-626
14. Ozols RF, Ostchega Y, Curt G, et al. (1987) High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 5:197-201
15. Kaye SB, Lewis CR, Paul J, et al. (1992) Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340:329-333
16. Murphy D, Crowther D, Renninson J, et al. (1993) A randomized dose intensity study in ovarian carcinoma comparing chemotherapy given at 4-week intervals for 6 cycles with half dose chemotherapy given for 12 cycles. Ann Oncol 4:377-383
17. Levin L, Simon R, Hryniuk W (1993) Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose-intensity analysis. J Natl Cancer Inst 85:1732-1742
18. McGuire WP, Hoskins WJ, Brady MF, et al. (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599
19. Colombo N, Pittelli MR, Parma G, et al. (1993) Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): a randomized study of conventional dose (DC) vs dose-intense (DI) cisplatin monochemotherapy (abstract). Proc Am Soc Clin Oncol 12:255
20. Conte PF, Bruzzone M, Carnino F, et al. (1996) High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14:351-356
21. Jakobsen A, Bertelsen K, Andersen JE, et al. (1997) Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 15:193-198
22. Benedetti-Panici P, Greggi S, Scambia G, et al. (1995) High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 27:133-138
23. Legros M, Dauplat J, Fleury J, et al. (1997) High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long term results. J Clin Oncol 15:1302-1308
24. Stiff PJ, Bayer R, Kerger C, et al. (1997) High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 15:1309-1317
25. Omura GA, Brady MF, Homesley HD, et al. (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150
26. Advanced Ovarian Cancer Trialists Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 303:884-893
27. Gloeckler Ries LA (1993) Ovarian cancer. Survival and treatment difference by age. Cancer 71:524-529
28. Fennelly DW, Aghajanian C, Shapiro F, et al. (1997) Dose escalation of Paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Semin Oncol 24 (Suppl 2):s2-26-30
29. Shpall EJ, Clarke-Person D, Soper JT, et al. (1990) High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38:386-391
30. Fennelly D, Wasserheit C, Schneider J, et al. (1994) Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cell and filgrastim: a phase I trial. Cancer Res 54:6137-6142
31. Murakami M, Shinozuka T, Miyamoto T, et al. (1993) The impact of autologous bone marrow transplantation on hematopoietic recovery after high-dose cyclophosphamide, doxorubicin, and cisplatin chemotherapy for patients with gynecological malignancies. Asia-Oceania J Obstet Gynaecol 19:85-93